Comparing two treatments for inoperable primary liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial is designed to evaluate the efficacy and safety of stereotactic radiosurgery versus radiofrequency ablation in patients with inoperable primary liver cancer. The study will enroll patients who have tumors located near critical structures and are not candidates for surgery. Participants will be randomly assigned to receive either stereotactic radiotherapy or radiofrequency ablation, with the aim of determining which treatment is more effective. A total of 130 patients will be recruited for this trial, with 65 in each treatment group.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Prior to implementing any trial-related procedures, written informed consent must be signed;
2. Age ≥ 18 years and ≤ 75 years;
3. Child-Pugh score ≤ 7;KPS score ≥ 70;
4. The patient must be clearly diagnosed with hepatocellular carcinoma, usually confirmed through imaging (CT, MRI) or histological examination (biopsy);
5. The tumor is located near major blood vessels/diaphragm/liver capsule/liver hilum;
6. Surgically assessed as inoperable hepatocellular carcinoma or recurrence of primary hepatocellular carcinoma within 2 years after radical treatment;
7. According to the criteria for evaluating the efficacy of solid tumors, there should be at least one measurable lesion by imaging, with the lesion size not exceeding 5 cm; total number of lesions ≤ 3;
8. No previous anti-tumor treatment;
9. Normal liver (liver volume minus tumor volume) is sufficient;
10. Normal major organ functions, including blood routine tests \[absolute neutrophil count (ANC) ≥ 1.5 × 10\^9, platelets ≥ 70 × 10\^9, hemoglobin ≥ 80 g/L\], liver function tests \[bilirubin \< 3.0 mg/dL, international normalized ratio (INR) \< 1.7, albumin ≥ 2.8 g/dL, aspartate transaminase (AST)/alanine transaminase (ALT) \< 6\], serum creatinine \< 1.5 times the upper limit of normal, or creatinine clearance ≥ 60 mL/min;
11. Stable respiration for more than 10 minutes;
12. Expected survival time \> 2 years.

Exclusion Criteria:

1. Possible surgical intervention;
2. Presence of other serious comorbidities, such as uncontrolled cardiovascular diseases, pulmonary diseases, or dysfunction of other organs, where the overall health status is poor and may result in treatment intolerance;
3. Severe liver dysfunction exceeding the specific criteria defined in the trial;
4. Other malignancies diagnosed within 5 years prior to the first treatment or at the time of diagnosis of hepatocellular carcinoma;
5. Significant clinically meaningful bleeding symptoms or a clear bleeding tendency within 3 months prior to enrollment;
6. Currently participating in an interventional clinical trial treatment, or having received other investigational drugs or used investigational devices within 4 weeks before the first treatment;
7. Previous treatment with anti-target tumor therapies;
8. History of upper abdominal radiotherapy;
9. Uncontrolled active comorbidities;
10. Not meeting the expected survival prognosis or unable to provide informed consent.

Where it's running

• Department of Hepatobiliary Oncology and Radiation Oncology,Tianjin Medical University Cancer Institute & Hospital,Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Song Tianqiang T Song, MD
• Email: tjchi@hotmail.com
• Phone: +86 18622221077

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma methylation test for detecting liver cancer recurrence (GNB4 and Riplet)

  This test sees if a blood-based methylation assay measuring GNB4 and Riplet can detect return of primary liver cancer in people who had hepatectomy, liver transplant, ablation, or TACE.

  Recruiting Wuhan Ammunition Life-tech Co., Ltd · Wuhan, Hubei · NCT07466602

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Combining advanced ultrasound and molecular analyses to map tumor differences in liver cancer

  This project tries combining multiple ultrasound techniques with molecular (multi-omics) tests to see if they can better characterize tumors and guide care for adults with primary liver cancer who are scheduled for surgery.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07101237

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

• Evaluation of the HistoSonics Edison System for treating liver tumors

  This study is testing how well the HistoSonics Edison System works for treating liver tumors and how different factors affect the treatment's success in real patients.

  Recruiting at 32 sites HistoSonics, Inc. · Mobile, Alabama and 34 other locations · NCT06486454

• Evaluating a protein as a marker for liver cancer recurrence

  This study is trying to see if higher levels of a certain protein in the blood can help predict if liver cancer will come back in people who have already had it.

  Recruiting Nanjing Medical University · Nanjing, Jiangsu · NCT06430983

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.